DOCSLIB.ORG

Folate Receptor Β Regulates Integrin Cd11b/CD18 Adhesion of a Macrophage Subset to Collagen

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Folate Receptor β Regulates Integrin CD11b/CD18 Adhesion of a Macrophage Subset to Collagen This information is current as Christian Machacek, Verena Supper, Vladimir Leksa, Goran of September 25, 2021. Mitulovic, Andreas Spittler, Karel Drbal, Miloslav Suchanek, Anna Ohradanova-Repic and Hannes Stockinger J Immunol 2016; 197:2229-2238; Prepublished online 17 August 2016; doi: 10.4049/jimmunol.1501878 Downloaded from http://www.jimmunol.org/content/197/6/2229 Supplementary http://www.jimmunol.org/content/suppl/2016/08/17/jimmunol.150187 Material 8.DCSupplemental http://www.jimmunol.org/ References This article cites 49 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/197/6/2229.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 25, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Folate Receptor b Regulates Integrin CD11b/CD18 Adhesion of a Macrophage Subset to Collagen Christian Machacek,* Verena Supper,* Vladimir Leksa,*,† Goran Mitulovic,‡ Andreas Spittler,x Karel Drbal,{,1 Miloslav Suchanek,{ Anna Ohradanova-Repic,* and Hannes Stockinger* Folate, also known as vitamin B9, is necessary for essential cellular functions such as DNA synthesis, repair, and methylation. It is supplied to the cell via several transporters and receptors, including folate receptor (FR) b, a GPI-anchored protein belonging to the folate receptor family. As FRb shows a restricted expression to cells of myeloid origin and only a subset of activated macrophages and placental cells have been shown to express functional FRb, it represents a promising target for future thera- peutic strategies. In this study, we performed affinity purification and mass spectrometric analysis of the protein microenviron- ment of FRb in the plasma membrane of human FRb+ macrophages and FRb-transduced monocytic THP-1 cells. In this manner, Downloaded from we identified a novel role of FRb: that is, we report functional interactions of FRb with receptors mediating cellular adhesion, in particular the CD11b/CD18 b2 integrin heterodimer complement receptor type 3/Mac-1. This interaction results in impeded adhesion of FRb+ human primary macrophages and THP-1 cells to collagen in comparison with their FRb2 counterparts. We further show that FRb is only expressed by human macrophages when differentiated with M-CSF. These findings thus identify FRb as a novel CD11b/CD18 regulator for trafficking and homing of a subset of macrophages on collagen. The Journal of Immunology, 2016, 197: 2229–2238. http://www.jimmunol.org/ olate receptor (FR) b, a GPI-anchored protein belonging to Unlike the broadly expressed reduced folate carrier (SLC19A1) the folate receptor family (1), constitutes one of the pathways and proton-coupled folate transporter (SLC46A1) (6), FRb shows F providing folic acid necessary for essential cellular functions a restricted expression to cells of the myeloid origin, and only a such as DNA synthesis, repair, and methylation (2, 3). Contrary to the subset of activated macrophages and placental cells has been embryonically lethal FRa knockout mice (4), genomic ablation of shown to express functional FRb (7). Macrophages show remark- FRb has no reported phenotype except for an increased risk of em- able plasticity, and their phenotype can vary greatly depending on bryonic lethality through arsenate or valproic acid exposure (5). the stimulus. On the one hand, classically activated (e.g., LPS plus by guest on September 25, 2021 However, a comprehensive functional analysis of this receptor, as IFN-g) macrophages (M1 type) drive Th1 responses and mediate well as an identification of its interacting proteins, is still missing. host defense from bacteria as well as viruses and propagate anti- tumor functions. On the other hand, alternatively activated (e.g., by *Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infecti- Th2 cytokine IL-4) macrophages (M2 type) induce a Th2-mediated ology and Immunology, Medical University of Vienna, 1090 Vienna, Austria; immune response against parasites and fungi and display an anti- † Laboratory of Molecular Immunology, Institute of Molecular Biology, Slovak Acad- inflammatory as well as wound healing phenotype (8). Reports that emy of Sciences, 845 51 Bratislava, Slovakia; ‡Department of Clinical Chemistry and Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria; xDepart- FRb is expressed on subpopulations of monocytes and macro- ment of Surgery and Core Facility Flow Cytometry, Medical University of Vienna, { phages in rheumatoid arthritis (9, 10), on M2 macrophages in 1090 Vienna, Austria; and EXBIO Praha, 252 42 Vestec, Czech Republic cancer (11, 12) as well as on myeloid leukemia cells (13, 14), have 1 Current address: Department of Cell Biology, Faculty of Science, Charles University placed attention on FRb as a tool for targeting pathogenic and in Prague, Prague, Czech Republic. malignant myeloid cells. ORCIDs: 0000-0003-2831-600X (V.S.); 0000-0003-1964-3965 (G.M.); 0000-0003- 2657-6836 (A.S.); 0000-0003-4450-4625 (K.D.); 0000-0002-8005-8522 (A.O.-R.); As GPI-anchored proteins are inserted into the outer leaflet of the 0000-0001-6404-4430 (H.S.). cell membrane, they require interaction partners in the form of Received for publication August 20, 2015. Accepted for publication July 14, 2016. transmembrane proteins to transmit outside–in signals. Therefore, This work was supported by the European Union Seventh Framework Programme characterization of the protein microenvironment of FRb is one (FP7/2007-2013) under Grant Agreement NMP4-LA-2009-228827 NANOFOL. V.L. possible route to investigate its function. Recently, a functional was supported by Austrian Science Fund Grant P22908 and Slovak Scientific Grant interaction between FRa and gp130 was reported (15), explaining Agency Grant 2/0063/14. how FRa is able to convey a proliferative advantage to cancer Address correspondence and reprint requests to Prof. Hannes Stockinger and Dr. Anna Ohradanova-Repic, Institute for Hygiene and Applied Immunology, cells. As FRb exhibits restricted expression to cells of myeloid Center for Pathophysiology, Infectiology and Immunology, Medical University origin, we investigated whether FRb is involved in the regulation of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria. E-mail addresses: hannes. of immune cell function. [email protected] (H.S.) and [email protected] (A.O.-R.) One central function is the ability of immune cells to locate in The online version of this article contains supplemental material. areas with active inflammation. This, however, can drive disease Abbreviations used in this article: AF, Alexa Fluor; ATRA, all-trans retinoic acid; CR3, complement receptor type 3; ECM, extracellular matrix; FR, folate receptor; progression in instances of chronic inflammation (e.g., rheumatoid HA, hemagglutinin; IP, immunoprecipitation; LC-MS/MS, liquid chromatography– arthritis) (16). The integrin family of proteins constitutes a major MS/MS; MFI, mean fluorescence intensity; MS, mass spectrometry; MS/MS, tandem factor in the regulation of leukocyte trafficking (17), and its MS; TFA, trifluoroacetic acid; vD , 1,25-dihydroxyvitamin D . 3 3 members were shown to associate with various GPI-anchored Copyright Ó 2016 by The American Association of Immunologists, Inc. 0022-1767/16/$30.00 proteins that modulate their activity (18–20). In this study, we www.jimmunol.org/cgi/doi/10.4049/jimmunol.1501878 2230 CD11b/CD18 ADHESION TO COLLAGEN REGULATED BY FRb report a functional interaction of FRb with the CD11b/CD18 (A-11070) and AF 680–conjugated goat anti-mouse IgG were purchased integrin heterodimer Mac-1 resulting in modulated adhesion to from Invitrogen. Anti-hemagglutinin (HA) mAb (clone 12CA5) and the extracellular matrix (ECM) component collagen. peroxidase-conjugated anti-mouse IgG (A9044) were purchased from Sigma-Aldrich. IRDye 800CW–conjugated donkey anti-rabbit IgG was purchased from LI-COR Biosciences (Lincoln, NE). AF 488–conjugated Materials and Methods goat-anti-mouse IgG (H+L) was purchased from Thermo Fischer Sci- Cell isolation and cultivation entific (Waltham, MA). Human PBMCs were isolated from leukocyte reduction chambers of Flow cytometry healthy adult blood donors by density gradient centrifugation using Cells were detached using 1.5 mM EDTA in HBSS. Cells were washed with Lymphoprep (Axis-Shield, Oslo, Norway). CD14+ monocytes were purified staining buffer (PBS supplemented with 1% BSA [Carl Roth, Karlsruhe, from PBMCs by MACS using CD14 microbeads (Miltenyi Biotec, Ber- Germany] and 0.02% NaN ), and nonspecific binding of the mAbs to Fc gisch Gladbach, Germany) with a minimal purity of 98%. THP-1 cells 3 receptors was prevented by blocking
Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
  • Tools for Cell Therapy and Immunoregulation

    Tools for Cell Therapy and Immunoregulation

    RnDSy-lu-2945 Tools for Cell Therapy and Immunoregulation Target Cell TIM-4 SLAM/CD150 BTNL8 PD-L2/B7-DC B7-H1/PD-L1 (Human) Unknown PD-1 B7-1/CD80 TIM-1 SLAM/CD150 Receptor TIM Family SLAM Family Butyrophilins B7/CD28 Families T Cell Multiple Co-Signaling Molecules Co-stimulatory Co-inhibitory Ig Superfamily Regulate T Cell Activation Target Cell T Cell Target Cell T Cell B7-1/CD80 B7-H1/PD-L1 T cell activation requires two signals: 1) recognition of the antigenic peptide/ B7-1/CD80 B7-2/CD86 CTLA-4 major histocompatibility complex (MHC) by the T cell receptor (TCR) and 2) CD28 antigen-independent co-stimulation induced by interactions between B7-2/CD86 B7-H1/PD-L1 B7-1/CD80 co-signaling molecules expressed on target cells, such as antigen-presenting PD-L2/B7-DC PD-1 ICOS cells (APCs), and their T cell-expressed receptors. Engagement of the TCR in B7-H2/ICOS L 2Ig B7-H3 (Mouse) the absence of this second co-stimulatory signal typically results in T cell B7-H1/PD-L1 B7/CD28 Families 4Ig B7-H3 (Human) anergy or apoptosis. In addition, T cell activation can be negatively regulated Unknown Receptors by co-inhibitory molecules present on APCs. Therefore, integration of the 2Ig B7-H3 Unknown B7-H4 (Mouse) Receptors signals transduced by co-stimulatory and co-inhibitory molecules following TCR B7-H5 4Ig B7-H3 engagement directs the outcome and magnitude of a T cell response Unknown Ligand (Human) B7-H5 including the enhancement or suppression of T cell proliferation, B7-H7 Unknown Receptor differentiation, and/or cytokine secretion.
  • CD2 Molecules Redistribute to the Uropod During T Cell Scanning: Implications for Cellular Activation and Immune Surveillance

    CD2 Molecules Redistribute to the Uropod During T Cell Scanning: Implications for Cellular Activation and Immune Surveillance

    CD2 molecules redistribute to the uropod during T cell scanning: Implications for cellular activation and immune surveillance Elena V. Tibaldi*†, Ravi Salgia†‡, and Ellis L. Reinherz*†§ *Laboratory of Immunobiology and ‡Division of Adult Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, and †Department of Medicine, Harvard Medical School, Boston, MA 02115 Communicated by Stuart F. Schlossman, Dana-Farber Cancer Institute, Boston, MA, April 9, 2002 (received for review February 14, 2002) Dynamic binding between CD2 and CD58 counter-receptors on op- cells, whereas its counter-receptor CD58 is expressed on a posing cells optimizes immune recognition through stabilization of diverse array of nucleated and non-nucleated cells including cell–cell contact and juxtaposition of surface membranes at a distance APCs and stromal cells (reviewed in refs. 11 and 12). CD2 suitable for T cell receptor–ligand interaction. Digitized time-lapse functions in both T cell adhesion and activation processes (13). Ϸ differential interference contrast and immunofluorescence micros- Of note, the weak affinity of the CD2-CD58 interaction (Kd copy on living cells now show that this binding also induces T cell 1 ␮M) is associated with remarkably fast on and off rates that polarization. Moreover, CD2 can facilitate motility of T cells along foster rapid and extensive exchange between CD2 and CD58 antigen-presenting cells via a movement referred to as scanning. Both partners on opposing cell surfaces (14–16). These biophysical activated CD4 and CD8 T cells are able to scan antigen-presenting cells characteristics are reminiscent of the selectin–ligand interactions surfaces in the absence of cognate antigen.
  • Prospects for NK Cell Therapy of Sarcoma

    Prospects for NK Cell Therapy of Sarcoma

    cancers Review Prospects for NK Cell Therapy of Sarcoma Mieszko Lachota 1 , Marianna Vincenti 2 , Magdalena Winiarska 3, Kjetil Boye 4 , Radosław Zago˙zd˙zon 5,* and Karl-Johan Malmberg 2,6,* 1 Department of Clinical Immunology, Doctoral School, Medical University of Warsaw, 02-006 Warsaw, Poland; [email protected] 2 Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 3 Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; [email protected] 4 Department of Oncology, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 5 Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland 6 Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 86 Stockholm, Sweden * Correspondence: [email protected] (R.Z.); [email protected] (K.-J.M.) Received: 15 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Sarcomas are a group of aggressive tumors originating from mesenchymal tissues. Patients with advanced disease have poor prognosis due to the ineffectiveness of current treatment protocols. A subset of lymphocytes called natural killer (NK) cells is capable of effective surveillance and clearance of sarcomas, constituting a promising tool for immunotherapeutic treatment. However, sarcomas can cause impairment in NK cell function, associated with enhanced tumor growth and dissemination. In this review, we discuss the molecular mechanisms of sarcoma-mediated suppression of NK cells and their implications for the design of novel NK cell-based immunotherapies against sarcoma.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Cancer-Associated Fibroblasts Promote Prostate Tumor Growth And

    Cancer-Associated Fibroblasts Promote Prostate Tumor Growth And

    Neuwirt et al. Cell Communication and Signaling (2020) 18:11 https://doi.org/10.1186/s12964-019-0505-5 RESEARCH Open Access Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis Hannes Neuwirt1, Jan Bouchal2, Gvantsa Kharaishvili2, Christian Ploner3, Karin Jöhrer4,5, Florian Pitterl6, Anja Weber7, Helmut Klocker7 and Iris E. Eder7* Abstract Background: Androgen receptor targeted therapies have emerged as an effective tool to manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy resistance represents a major challenge in the clinical management of patients, also because the molecular mechanisms behind therapy resistance are not yet fully understood. In the present study, we therefore aimed to identify novel targets to intervene with therapy resistance using gene expression analysis of PCa co-culture spheroids where PCa cells are grown in the presence of cancer-associated fibroblasts (CAFs) and which have been previously shown to be a reliable model for antiandrogen resistance. Methods: Gene expression changes of co-culture spheroids (LNCaP and DuCaP seeded together with CAFs) were identified by Illumina microarray profiling. Real-time PCR, Western blotting, immunohistochemistry and cell viability assays in 2D and 3D culture were performed to validate the expression of selected targets in vitro and in vivo. Cytokine profiling was conducted to analyze CAF-conditioned medium. Results: Gene expression analysis of co-culture spheroids revealed that CAFs induced a significant upregulation of cholesterol and steroid biosynthesis pathways in PCa cells. Cytokine profiling revealed high amounts of pro- inflammatory, pro-migratory and pro-angiogenic factors in the CAF supernatant. In particular, two genes, 3-hydroxy- 3-methylglutaryl-Coenzyme A synthase 2 (HMGCS2) and aldo-keto reductase family 1 member C3 (AKR1C3), were significantly upregulated in PCa cells upon co-culture with CAFs.
  • Response Gene Expression That Modulates T Cell Induces a Differential Cytokine Tuberculosis Mycobacterium Dendritic Cells with I

    Response Gene Expression That Modulates T Cell Induces a Differential Cytokine Tuberculosis Mycobacterium Dendritic Cells with I

    Infection of Human Macrophages and Dendritic Cells with Mycobacterium tuberculosis Induces a Differential Cytokine Gene Expression That Modulates T Cell This information is current as Response of September 24, 2021. Elena Giacomini, Elisabetta Iona, Lucietta Ferroni, Minja Miettinen, Lanfranco Fattorini, Graziella Orefici, Ilkka Julkunen and Eliana M. Coccia J Immunol 2001; 166:7033-7041; ; Downloaded from doi: 10.4049/jimmunol.166.12.7033 http://www.jimmunol.org/content/166/12/7033 http://www.jimmunol.org/ References This article cites 51 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/166/12/7033.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Infection of Human Macrophages and Dendritic Cells with Mycobacterium tuberculosis Induces a Differential Cytokine Gene Expression That Modulates T Cell Response1 Elena Giacomini,* Elisabetta Iona,† Lucietta Ferroni,* Minja Miettinen,‡ Lanfranco Fattorini,† Graziella Orefici,† Ilkka Julkunen,‡ and Eliana M.
  • Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

    Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

    King’s Research Portal DOI: 10.3389/fimmu.2019.00453 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Khair, D. O., Bax, H. J., Mele, S., Crescioli, S., Pellizzari, G., Khiabany, A., Nakamura, M., Harris, R. J., French, E., Hoffmann, R. M., Williams, I. P., Cheung, K. K. A., Thair, B., Beales, C. T., Touizer, E., Signell, A. W., Tasnova, N. L., Spicer, J. F., Josephs, D. H., ... Karagiannis, S. N. (2019). Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Frontiers in Immunology , (MAR), [453]. https://doi.org/10.3389/fimmu.2019.00453 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells

    CD Markers Are Routinely Used for the Immunophenotyping of Cells

    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
  • Systematic Identification of Cancer Cell Vulnerabilities to Natural Killer Cell

    Systematic Identification of Cancer Cell Vulnerabilities to Natural Killer Cell

    bioRxiv preprint doi: https://doi.org/10.1101/597567; this version posted April 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 2 Systematic identification of cancer cell vulnerabilities to natural killer 3 cell-mediated immune surveillance 4 5 Matthew F. Pech, Jacqueline E. Villalta, Leanne J.G. Chan, Samir Kharbanda, Jonathon J. 6 O’Brien, Fiona E. McAllister, Ari J. Firestone, Calvin H. Jan, Jeff Settleman# 7 8 Calico Life Sciences LLC, 1170 Veterans Boulevard, South San Francisco, CA, United States 9 #correspondence: [email protected] 10 1 bioRxiv preprint doi: https://doi.org/10.1101/597567; this version posted April 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 11 Abstract 12 13 Only a subset of patients respond to therapies that stimulate T-cell responses to cancer, 14 highlighting the need for alternative strategies to promote anti-cancer immunity. Here, we 15 performed genome-scale CRISPR-Cas9 screens in a human MHC-deficient leukemic cancer cell 16 line to systematically identify perturbations that enhance natural killer (NK) effector functions. 17 Our screens defined critical components of the tumor-immune synapse and highlighted the 18 importance of cancer cell interferon-g (IFNg) signaling in promoting NK activity.
  • CD14-Expressing Cancer Cells Establish the Inflammatory and Proliferative Tumor Microenvironment in Bladder Cancer

    CD14-Expressing Cancer Cells Establish the Inflammatory and Proliferative Tumor Microenvironment in Bladder Cancer

    CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer Ming T. Cheaha,b,1, James Y. Chena,b, Debashis Sahooa,b,c, Humberto Contreras-Trujilloa,b, Anne K. Volkmera,b,d, Ferenc A. Scheerene, Jens-Peter Volkmera,b,1,2, and Irving L. Weissmana,b,1,2 aInstitute of Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305; bLudwig Center for Cancer Stem Cell Research and Medicine, Stanford University, Stanford, CA 94305; cDepartment of Pediatrics, University of California, San Diego, La Jolla, CA 92093; dDepartment of Obstetrics and Gynecology, University of Dusseldorf, 40225 Dusseldorf, Germany; and eDivision of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands Contributed by Irving L. Weissman, February 14, 2015 (sent for review May 4, 2014) Nonresolving chronic inflammation at the neoplastic site is consis- levels of CD14. Here, we investigate the strategies used by tently associated with promoting tumor progression and poor patient KRT14+ CD14-high BC cells to promote tumor growth. outcomes. However, many aspects behind the mechanisms that establish this tumor-promoting inflammatory microenvironment re- Results main undefined. Using bladder cancer (BC) as a model, we found that KRT14+ Basal BC Cells Express Higher Levels of CD14. We have CD14-high cancer cells express higher levels of numerous inflamma- previously identified KRT14 expression as a marker specific for tion mediators and form larger tumors compared with CD14-low cells. the primitive/basal differentiation state in BC (32). We further CD14 antigen is a glycosyl-phosphatidylinositol (GPI)-linked glycopro- determined that CD90+ cells, which express higher levels of tein and has been shown to be critically important in the signaling KRT14, represent the tumorigenic subpopulation in primary pa- pathways of Toll-like receptor (TLR).
  • Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy

    Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy

    Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/1078-0432.CCR-15-2428 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy Elodie Picarda1, Kim C. Ohaegbulam1, Xingxing Zang1,2,3 1Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York. 2Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. 3Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. Note: E. Picarda and K.C. Ohaegbulam contributed equally to this article. Corresponding author: Xingxing Zang, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461. Phone: 718-430-4155; Fax: 718-430-8711; E-mail: [email protected] Running Title: Cancer Immunotherapies against B7-H3 1 Downloaded from clincancerres.aacrjournals.org on October 2, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 20, 2016; DOI: 10.1158/1078-0432.CCR-15-2428 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract B7-H3 (CD276) is an important immune checkpoint member of the B7 and CD28 families. Induced on antigen presenting cells, B7-H3 plays an important role in the inhibition of T cell function. Importantly, B7-H3 is highly overexpressed on a wide range of human solid cancers and often correlates with both negative prognosis and poor clinical outcome in patients. Challenges remain to identify the receptor(s) of B7-H3 and thus better elucidate the role of the B7-H3 pathway in immune responses and tumor evasion.